Illumina, Inc. $ILMN Shares Sold by Azzad Asset Management Inc. ADV

Azzad Asset Management Inc. ADV decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 25.1% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 8,401 shares of the life sciences company’s stock after selling 2,817 shares during the quarter. Azzad Asset Management Inc. ADV’s holdings in Illumina were worth $1,036,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ILMN. Invesco Ltd. grew its stake in Illumina by 97.0% during the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after buying an additional 1,352,731 shares during the period. AQR Capital Management LLC raised its stake in shares of Illumina by 30.3% in the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after acquiring an additional 1,028,099 shares during the period. Morgan Stanley raised its stake in shares of Illumina by 66.0% in the 4th quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock valued at $331,710,000 after acquiring an additional 1,005,474 shares during the period. Nordea Investment Management AB lifted its holdings in shares of Illumina by 2,792.2% during the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after acquiring an additional 911,843 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. acquired a new position in shares of Illumina during the 1st quarter valued at $106,462,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina is being highlighted by market commentary as a biotech and life sciences momentum name, with analysts pointing to stronger earnings trends and sector leadership in healthcare. Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN
• Positive Sentiment: Several articles frame ILMN as a strong momentum stock and note that it has outperformed recently, reinforcing bullish trading interest. Illumina (ILMN) Is Up 6.87% in One Week: What You Should Know
• Positive Sentiment: Illumina announced new executive appointments, naming Michael Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, which may be viewed as a move to strengthen commercial execution and governance. Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
• Positive Sentiment: Illumina also announced it will report second-quarter 2026 results on July 30, keeping attention on upcoming fundamentals and guidance. Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
• Neutral Sentiment: Coverage also repeated bullish valuation and “mooning stock” themes, but these were largely commentary pieces rather than new company-specific developments. Illumina Stock Gains 43.7% in 2026: What’s Powering the Rally?
• Negative Sentiment: Short-interest data showed no meaningful bearish positioning change, so it does not currently add fresh downside pressure, though the report itself was unusual and offered little real signal. Illumina (ILMN) Stock May Be 27% Undervalued Following Strong Q1 Results

Wall Street Analyst Weigh In

A number of analysts recently weighed in on ILMN shares. Piper Sandler upped their price target on shares of Illumina from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 1st. Sanford C. Bernstein assumed coverage on Illumina in a research report on Friday, June 26th. They issued a “market perform” rating and a $185.00 price objective on the stock. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research report on Thursday, May 14th. Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Monday. Finally, JPMorgan Chase & Co. upgraded Illumina from a “neutral” rating to an “overweight” rating and increased their target price for the company from $125.00 to $185.00 in a research note on Wednesday, June 10th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $150.44.

Insider Buying and Selling

In other news, insider Scott M. Davies sold 615 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $180.00, for a total transaction of $110,700.00. Following the completion of the transaction, the insider directly owned 20,953 shares in the company, valued at approximately $3,771,540. This represents a 2.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at $3,456,500.81. The trade was a 3.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,003,769 shares of company stock worth $155,710,908 over the last 90 days. 2.90% of the stock is currently owned by corporate insiders.

Illumina Stock Down 1.8%

Shares of Illumina stock opened at $190.20 on Friday. The business has a 50-day moving average of $161.31 and a 200-day moving average of $141.50. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The company has a market capitalization of $28.78 billion, a PE ratio of 34.58, a P/E/G ratio of 3.63 and a beta of 1.47. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $196.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company’s revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts forecast that Illumina, Inc. will post 5.21 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.